APO Research
Talk to an analyst

APO RESEARCH · REPORT

Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19)

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Industry Growth and Trends Forecast to 2032

2 January 202696 pages

Choose your research edition.

Industry ResearchHuman Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Industry Growth and Trends Forecast to 203296 pages · $3,450 USDMarket StructureGlobal Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032188 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) include Weiguang Biological, CTBB, Shanghai RAAS, Nanyue Biopharming, Hualan Bio, Sinopharm, Guangdong Shuagnlin Bio-pharmacy, Boya-Bio and Beijing Tiantan Biological Products, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19).

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market by Company

Weiguang Biological

CTBB

Shanghai RAAS

Nanyue Biopharming

Hualan Bio

Sinopharm

Guangdong Shuagnlin Bio-pharmacy

Boya-Bio

Beijing Tiantan Biological Products

Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Segment by Type

1.25g/25ml

10g/200ml

1g/20ml

2.5g/50ml

5g/100ml

Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Segment by Application

Hospital

Clinic

Others

Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of 1.25g/25ml Table 2. Major Company of 10g/200ml Table 3. Major Company of 1g/20ml Table 4. Major Company of 2.5g/50ml Table 5. Major Company of 5g/100ml Table 6. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 7. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Type (2021-2026) & (K Units) Table 8. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share in Volume by Type (2021-2026) Table 9. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Type (2021-2026) & (US$ Million) Table 10. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share in Value by Type (2021-2026) Table 11. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Price by Type (2021-2026) & (US$/Unit) Table 12. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Type (2027-2032) & (K Units) Table 13. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share in Volume by Type (2027-2032) Table 14. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Type (2027-2032) & (US$ Million) Table 15. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share in Value by Type (2027-2032) Table 16. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Price by Type (2027-2032) & (US$/Unit) Table 17. North America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Type (2021-2026) & (K Units) Table 18. North America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Type (2021-2026) & (US$ Million) Table 19. Europe Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Type (2021-2026) & (K Units) Table 20. Europe Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Type (2021-2026) & (US$ Million) Table 21. Asia-Pacific Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Type (2021-2026) & (K Units) Table 22. Asia-Pacific Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Type (2021-2026) & (US$ Million) Table 23. Latin America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Type (2021-2026) & (K Units) Table 24. Latin America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Type (2021-2026) & (US$ Million) Table 25. Middle East and Africa Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Type (2021-2026) & (K Units) Table 26. Middle East and Africa Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Type (2021-2026) & (US$ Million) Table 27. Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Industry Trends Table 28. Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Industry Drivers Table 29. Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Industry Opportunities and Challenges Table 30. Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Industry Restraints Table 31. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Revenue by Company (US$ Million) & (2021-2026) Table 32. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Market Share by Company (2021-2026) Table 33. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Company (2021-2026) & (K Units) Table 34. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Share by Company (2021-2026) Table 35. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Price by Company (2021-2026) & (US$/Unit) Table 36. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Industry Company Ranking, 2024 VS 2025 VS 2026 Table 37. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Major Company Production Sites and Headquarters Table 38. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Company, Product Type & Application Table 39. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Company Establishment Date Table 40. Global Company Market Concentration Ratio (CR5 and HHI) Table 41. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 42. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 43. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Region (2021-2026) & (K Units) Table 44. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share in Volume by Region (2021-2026) Table 45. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Region (2021-2026) & (US$ Million) Table 46. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share in Value by Region (2021-2026) Table 47. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 48. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Region (2027-2032) & (K Units) Table 49. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share in Volume by Region (2027-2032) Table 50. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Region (2027-2032) & (US$ Million) Table 51. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share in Value by Region (2027-2032) Table 52. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 53. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 54. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Application (2021-2026) & (K Units) Table 55. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share in Volume by Application (2021-2026) Table 56. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Application (2021-2026) & (US$ Million) Table 57. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share in Value by Application (2021-2026) Table 58. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Price by Application (2021-2026) & (US$/Unit) Table 59. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Application (2027-2032) & (K Units) Table 60. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share in Volume by Application (2027-2032) Table 61. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Application (2027-2032) & (US$ Million) Table 62. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share in Value by Application (2027-2032) Table 63. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Price by Application (2027-2032) & (US$/Unit) Table 64. North America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Application (2021-2026) & (K Units) Table 65. North America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Application (2021-2026) & (US$ Million) Table 66. Europe Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Application (2021-2026) & (K Units) Table 67. Europe Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Application (2021-2026) & (US$ Million) Table 68. Asia-Pacific Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Application (2021-2026) & (K Units) Table 69. Asia-Pacific Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Application (2021-2026) & (US$ Million) Table 70. Latin America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Application (2021-2026) & (K Units) Table 71. Latin America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Application (2021-2026) & (US$ Million) Table 72. Middle East and Africa Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Application (2021-2026) & (K Units) Table 73. Middle East and Africa Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Application (2021-2026) & (US$ Million) Table 74. Weiguang Biological Company Information Table 75. Weiguang Biological Business Overview Table 76. Weiguang Biological Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. Weiguang Biological Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Product Portfolio Table 78. Weiguang Biological Recent Development Table 79. CTBB Company Information Table 80. CTBB Business Overview Table 81. CTBB Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. CTBB Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Product Portfolio Table 83. CTBB Recent Development Table 84. Shanghai RAAS Company Information Table 85. Shanghai RAAS Business Overview Table 86. Shanghai RAAS Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. Shanghai RAAS Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Product Portfolio Table 88. Shanghai RAAS Recent Development Table 89. Nanyue Biopharming Company Information Table 90. Nanyue Biopharming Business Overview Table 91. Nanyue Biopharming Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Nanyue Biopharming Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Product Portfolio Table 93. Nanyue Biopharming Recent Development Table 94. Hualan Bio Company Information Table 95. Hualan Bio Business Overview Table 96. Hualan Bio Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. Hualan Bio Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Product Portfolio Table 98. Hualan Bio Recent Development Table 99. Sinopharm Company Information Table 100. Sinopharm Business Overview Table 101. Sinopharm Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. Sinopharm Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Product Portfolio Table 103. Sinopharm Recent Development Table 104. Guangdong Shuagnlin Bio-pharmacy Company Information Table 105. Guangdong Shuagnlin Bio-pharmacy Business Overview Table 106. Guangdong Shuagnlin Bio-pharmacy Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. Guangdong Shuagnlin Bio-pharmacy Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Product Portfolio Table 108. Guangdong Shuagnlin Bio-pharmacy Recent Development Table 109. Boya-Bio Company Information Table 110. Boya-Bio Business Overview Table 111. Boya-Bio Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. Boya-Bio Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Product Portfolio Table 113. Boya-Bio Recent Development Table 114. Beijing Tiantan Biological Products Company Information Table 115. Beijing Tiantan Biological Products Business Overview Table 116. Beijing Tiantan Biological Products Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 117. Beijing Tiantan Biological Products Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Product Portfolio Table 118. Beijing Tiantan Biological Products Recent Development Table 119. North America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 120. North America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Country (2021-2026) & (K Units) Table 121. North America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share by Country (2021-2026) Table 122. North America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Forecast by Country (2027-2032) & (K Units) Table 123. North America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share Forecast by Country (2027-2032) Table 124. North America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 125. North America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Size by Country (2021-2026) & (US$ Million) Table 126. North America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Share by Country (2021-2026) Table 127. North America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Size Forecast by Country (2027-2032) & (US$ Million) Table 128. North America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Share Forecast by Country (2027-2032) Table 129. Europe Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 130. Europe Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Country (2021-2026) & (K Units) Table 131. Europe Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share by Country (2021-2026) Table 132. Europe Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Forecast by Country (2027-2032) & (K Units) Table 133. Europe Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share Forecast by Country (2027-2032) Table 134. Europe Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 135. Europe Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Size by Country (2021-2026) & (US$ Million) Table 136. Europe Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Share by Country (2021-2026) Table 137. Europe Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Size Forecast by Country (2027-2032) & (US$ Million) Table 138. Europe Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Share Forecast by Country (2027-2032) Table 139. Asia-Pacific Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 140. Asia-Pacific Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Country (2021-2026) & (K Units) Table 141. Asia-Pacific Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share by Country (2021-2026) Table 142. Asia-Pacific Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Forecast by Country (2027-2032) & (K Units) Table 143. Asia-Pacific Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share Forecast by Country (2027-2032) Table 144. Asia-Pacific Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 145. Asia-Pacific Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Size by Country (2021-2026) & (US$ Million) Table 146. Asia-Pacific Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Share by Country (2021-2026) Table 147. Asia-Pacific Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Size Forecast by Country (2027-2032) & (US$ Million) Table 148. Asia-Pacific Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Share Forecast by Country (2027-2032) Table 149. Latin America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 150. Latin America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Country (2021-2026) & (K Units) Table 151. Latin America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share by Country (2021-2026) Table 152. Latin America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Forecast by Country (2027-2032) & (K Units) Table 153. Latin America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share Forecast by Country (2027-2032) Table 154. Latin America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 155. Latin America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Size by Country (2021-2026) & (US$ Million) Table 156. Latin America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Share by Country (2021-2026) Table 157. Latin America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Size Forecast by Country (2027-2032) & (US$ Million) Table 158. Latin America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Share Forecast by Country (2027-2032) Table 159. Middle East and Africa Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 160. Middle East and Africa Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Country (2021-2026) & (K Units) Table 161. Middle East and Africa Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share by Country (2021-2026) Table 162. Middle East and Africa Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Forecast by Country (2027-2032) & (K Units) Table 163. Middle East and Africa Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share Forecast by Country (2027-2032) Table 164. Middle East and Africa Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 165. Middle East and Africa Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Size by Country (2021-2026) & (US$ Million) Table 166. Middle East and Africa Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Share by Country (2021-2026) Table 167. Middle East and Africa Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Size Forecast by Country (2027-2032) & (US$ Million) Table 168. Middle East and Africa Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Share Forecast by Country (2027-2032) Table 169. Key Raw Materials Table 170. Raw Materials Key Suppliers Table 171. Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Distributors List Table 172. Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Customers List Table 173. Research Programs/Design for This Report Table 174. Authors List of This Report Table 175. Secondary Sources Table 176. Primary Sources List of Figures Figure 1. Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Image Figure 2. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Size (2021-2032) & (US$ Million) Figure 4. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales (2021-2032) & (K Units) Figure 5. 1.25g/25ml Image Figure 6. Global 1.25g/25ml Sales YoY Growth (2021-2032) & (K Units) Figure 7. 10g/200ml Image Figure 8. Global 10g/200ml Sales YoY Growth (2021-2032) & (K Units) Figure 9. 1g/20ml Image Figure 10. Global 1g/20ml Sales YoY Growth (2021-2032) & (K Units) Figure 11. 2.5g/50ml Image Figure 12. Global 2.5g/50ml Sales YoY Growth (2021-2032) & (K Units) Figure 13. 5g/100ml Image Figure 14. Global 5g/100ml Sales YoY Growth (2021-2032) & (K Units) Figure 15. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Size Overview by Type (2021-2032) & (US$ Million) Figure 16. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Share by Type 2025 VS 2032 Figure 17. North America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share in Volume by Type in 2025 Figure 18. North America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share in Value by Type in 2025 Figure 19. Europe Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share in Volume by Type in 2025 Figure 20. Europe Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share in Value by Type in 2025 Figure 21. Asia-Pacific Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share in Volume by Type in 2025 Figure 22. Asia-Pacific Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share in Value by Type in 2025 Figure 23. Latin America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share in Volume by Type in 2025 Figure 24. Latin America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share in Value by Type in 2025 Figure 25. Middle East and Africa Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share in Volume by Type in 2025 Figure 26. Middle East and Africa Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share in Value by Type in 2025 Figure 27. Global Top 5 and 10 Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Players Market Share by Revenue in 2025 Figure 28. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 29. Hospital Image Figure 30. Global Hospital Sales YoY Growth (2021-2032) & (K Units) Figure 31. Clinic Image Figure 32. Global Clinic Sales YoY Growth (2021-2032) & (K Units) Figure 33. Others Image Figure 34. Global Others Sales YoY Growth (2021-2032) & (K Units) Figure 35. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Size Overview by Application (2021-2032) & (US$ Million) Figure 36. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Share by Application 2025 VS 2032 Figure 37. North America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share in Volume by Application in 2025 Figure 38. North America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share in Value by Application in 2025 Figure 39. Europe Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share in Volume by Application in 2025 Figure 40. Europe Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share in Value by Application in 2025 Figure 41. Asia-Pacific Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share in Volume by Application in 2025 Figure 42. Asia-Pacific Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share in Value by Application in 2025 Figure 43. Latin America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share in Volume by Application in 2025 Figure 44. Latin America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share in Value by Application in 2025 Figure 45. Middle East and Africa Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share in Volume by Application in 2025 Figure 46. Middle East and Africa Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share in Value by Application in 2025 Figure 47. North America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 48. North America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Share by Country: 2021 VS 2025 VS 2032 Figure 49. North America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. North America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Europe Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 52. Europe Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Share by Country: 2021 VS 2025 VS 2032 Figure 53. Europe Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. Europe Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Asia-Pacific Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 56. Asia-Pacific Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Share by Country: 2021 VS 2025 VS 2032 Figure 57. Asia-Pacific Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Asia-Pacific Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Latin America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 60. Latin America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Share by Country: 2021 VS 2025 VS 2032 Figure 61. Latin America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. Latin America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Share by Country: 2021 VS 2025 VS 2032 Figure 63. Middle East and Africa Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 64. Middle East and Africa Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Share by Country: 2021 VS 2025 VS 2032 Figure 65. Middle East and Africa Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 66. Middle East and Africa Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Share by Country: 2021 VS 2025 VS 2032 Figure 67. Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Value Chain Figure 68. Key Raw Materials Price Figure 69. Manufacturing Cost Structure Figure 70. Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • 1.25g/25ml
  • 10g/200ml
  • 1g/20ml
  • 2.5g/50ml
  • 5g/100ml
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Weiguang Biological
  • CTBB
  • Shanghai RAAS
  • Nanyue Biopharming
  • Hualan Bio
  • Sinopharm
  • Guangdong Shuagnlin Bio-pharmacy
  • Boya-Bio
  • Beijing Tiantan Biological Products

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market by Type
  6. 1.3.1 1.25g/25ml
  7. 1.3.2 10g/200ml
  8. 1.3.3 1g/20ml
  9. 1.3.4 2.5g/50ml
  10. 1.3.5 5g/100ml
  11. 1.4 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Size by Type
  12. 1.4.1 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Size Overview by Type (2021-2032)
  13. 1.4.2 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Historic Market Size Review by Type (2021-2026)
  14. 1.4.3 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Forecasted Market Size by Type (2027-2032)
  15. 1.5 Key Regions Market Size by Type
  16. 1.5.1 North America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Breakdown by Type (2021-2026)
  17. 1.5.2 Europe Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Breakdown by Type (2021-2026)
  18. 1.5.3 Asia-Pacific Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Breakdown by Type (2021-2026)
  19. 1.5.4 South America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Breakdown by Type (2021-2026)
  20. 1.5.5 Middle East and Africa Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Industry Trends
  2. 2.2 Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Industry Drivers
  3. 2.3 Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Industry Opportunities and Challenges
  4. 2.4 Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue (2021-2026)
  2. 3.2 Global Top Players by Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales (2021-2026)
  3. 3.3 Global Top Players by Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Price (2021-2026)
  4. 3.4 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Major Company Production Sites & Headquarters
  6. 3.6 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Company, Product Type & Application
  7. 3.7 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Tier 1, Tier 2, and Tier 3
4 Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Regional Status and Outlook
  1. 4.1 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Historic Market Size by Region
  3. 4.2.1 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Forecasted Market Size by Region
  7. 4.3.1 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) by Application
  1. 5.1 Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market by Application
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Size by Application
  6. 5.2.1 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Weiguang Biological
  2. 6.1.1 Weiguang Biological Company Information
  3. 6.1.2 Weiguang Biological Business Overview
  4. 6.1.3 Weiguang Biological Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Weiguang Biological Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Product Portfolio
  6. 6.1.5 Weiguang Biological Recent Developments
  7. 6.2 CTBB
  8. 6.2.1 CTBB Company Information
  9. 6.2.2 CTBB Business Overview
  10. 6.2.3 CTBB Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 CTBB Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Product Portfolio
  12. 6.2.5 CTBB Recent Developments
  13. 6.3 Shanghai RAAS
  14. 6.3.1 Shanghai RAAS Company Information
  15. 6.3.2 Shanghai RAAS Business Overview
  16. 6.3.3 Shanghai RAAS Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Shanghai RAAS Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Product Portfolio
  18. 6.3.5 Shanghai RAAS Recent Developments
  19. 6.4 Nanyue Biopharming
  20. 6.4.1 Nanyue Biopharming Company Information
  21. 6.4.2 Nanyue Biopharming Business Overview
  22. 6.4.3 Nanyue Biopharming Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Nanyue Biopharming Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Product Portfolio
  24. 6.4.5 Nanyue Biopharming Recent Developments
  25. 6.5 Hualan Bio
  26. 6.5.1 Hualan Bio Company Information
  27. 6.5.2 Hualan Bio Business Overview
  28. 6.5.3 Hualan Bio Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Hualan Bio Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Product Portfolio
  30. 6.5.5 Hualan Bio Recent Developments
  31. 6.6 Sinopharm
  32. 6.6.1 Sinopharm Company Information
  33. 6.6.2 Sinopharm Business Overview
  34. 6.6.3 Sinopharm Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Sinopharm Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Product Portfolio
  36. 6.6.5 Sinopharm Recent Developments
  37. 6.7 Guangdong Shuagnlin Bio-pharmacy
  38. 6.7.1 Guangdong Shuagnlin Bio-pharmacy Company Information
  39. 6.7.2 Guangdong Shuagnlin Bio-pharmacy Business Overview
  40. 6.7.3 Guangdong Shuagnlin Bio-pharmacy Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Guangdong Shuagnlin Bio-pharmacy Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Product Portfolio
  42. 6.7.5 Guangdong Shuagnlin Bio-pharmacy Recent Developments
  43. 6.8 Boya-Bio
  44. 6.8.1 Boya-Bio Company Information
  45. 6.8.2 Boya-Bio Business Overview
  46. 6.8.3 Boya-Bio Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Boya-Bio Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Product Portfolio
  48. 6.8.5 Boya-Bio Recent Developments
  49. 6.9 Beijing Tiantan Biological Products
  50. 6.9.1 Beijing Tiantan Biological Products Company Information
  51. 6.9.2 Beijing Tiantan Biological Products Business Overview
  52. 6.9.3 Beijing Tiantan Biological Products Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Beijing Tiantan Biological Products Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Product Portfolio
  54. 6.9.5 Beijing Tiantan Biological Products Recent Developments
7 North America by Country
  1. 7.1 North America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Country
  2. 7.1.1 North America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Country (2021-2026)
  4. 7.1.3 North America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Forecast by Country (2027-2032)
  5. 7.2 North America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Size by Country
  6. 7.2.1 North America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Size by Country (2021-2026)
  8. 7.2.3 North America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Country
  2. 8.1.1 Europe Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Country (2021-2026)
  4. 8.1.3 Europe Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Size by Country
  6. 8.2.1 Europe Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Size by Country (2021-2026)
  8. 8.2.3 Europe Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Country
  2. 9.1.1 Asia-Pacific Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Size by Country
  6. 9.2.1 Asia-Pacific Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Country
  2. 10.1.1 South America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Country (2021-2026)
  4. 10.1.3 South America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Forecast by Country (2027-2032)
  5. 10.2 South America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Size by Country
  6. 10.2.1 South America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Size by Country (2021-2026)
  8. 10.2.3 South America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Country
  2. 11.1.1 Middle East and Africa Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Size by Country
  6. 11.2.1 Middle East and Africa Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Value Chain Analysis
  2. 12.1.1 Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Production Mode & Process
  7. 12.2 Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Distributors
  10. 12.2.3 Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst